{{Rsnum
|rsid=4495487
|Gene=JAK2
|Chromosome=9
|position=5072798
|Orientation=plus
|GMAF=0.2424
|Gene_s=JAK2
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=135
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 6.2 | 43.1 | 50.8
| HCB | 6.7 | 28.9 | 64.4
| JPT | 2.3 | 48.8 | 48.8
| YRI | 0.0 | 23.8 | 76.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 6.7 | 28.9 | 64.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=22251709
|Title=The C allele of the JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
|OA=1
}}
[http://blog.23andme.com/2012/03/05/snpwatch-the-jist-on-jak2-and-myeloproliferative-neoplasms/ 23andMe blog]
At rs12340895(G) (equivalent to rs12343867 in the study) had nearly four times higher odds of developing V617F-positive MPN compared to people without the disease. 23andMe recently replicated this association, though we see a smaller effect — in our database, people with a G at rs12340895 have about two times the odds of developing V617F-positive MPN compared to people without the disease. n A at rs3780374 in the JAK2 gene (equivalent to rs4495487 reported in the study and highly correlated with rs12343867) have about three times higher odds of developing V617F-positive MPN compared to individuals without the A version.

The following SNPs are (all) associated with the JAK2 46/1 haplotype that appears to predispose to V617F-positive neoplasms; since they are all part of one haplotype (and are not independent of one another), having one usually implies having the others as well.

*[[rs12343867]]
*[[rs12340895]]
*[[rs3780374]]
*[[rs4495487]]
*[[rs10974944]]